Muhammad Y. Sheikh

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Stephen A. Harrison, Zachary Goodman, Abdul Jabbar et al. · Journal of Hepatology · 2019 · 240 citations

Rheumatology, Antifibrotic Therapy, Fibrosis +5

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis

Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal et al. · Hepatology · 2011 · 162 citations · Full text

Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis

Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy et al. · Clinical Gastroenterology and Hepatology · 2016 · 89 citations · Full text

Urology, Metabolic Associated Steatohepatitis, Hepatology +11